LITERATUR

  1. Radwan P., Skrzydło-Radomańska B.: Rola mikroflory jelitowej w zdrowiu i chorobie. Gastroenterologia Praktyczna. 2/2013
  2. Drasar B.S., Hill M.J.: Human intestinal flora. Academic Press Inc., New York and San Francisco 1974; 186–192
  3. Bengmark S.: Modulation by enteral nutrition of the acute phase response and immune functions. Nutr. Hosp., 2003; 18: 1–5
  4. Górska S., Jarząb A., Gamian A.: Bakterie probiotyczne w przewodzie po- karmowym człowieka jako czynnik stymulujący układ odpornościowy. Postepy Hig Med Dosw. (online), 2009; 63: 653–667
  5. Fedorak R., Madsen K.: Probiotics and prebiotics in gastrointestinal disor- ders. Curr Opin Gastroenterol. 2004; 20: 146–155.
  6. Cukrowska B.: Mikrobiotyczna teoria rozwoju alergii – rola mikroflory je- litowej w aktywacji procesów przeciwalergicznych. Postępy neonatologii. Nr 1(12) 2008
  7. Krakowiak O, Nowak R. Mikroflora przewodu pokarmowego człowieka – znaczenie, rozwój, modyfikacje. Post Fitoter 2015; 3: 193–200.
  8. Nowak A, Libudzisz Z. Mikroorganizmy jelitowe człowieka. Stand Med. 2008; 1: 372–9.
  9. Borchers A.T., Selmi C., Meyers F., Keen C.L., Gershwin M.E.: Probiotics and immunity. J. Gastroenterol., 2009; 44, 26–46.
  10. Haevy P.M., Rowland I.R.: The gut microflora of the developing infant: mi- crobiology and metabolism, Microb Ecol Health Dis 1999; 11, 75–83
  11. Macpherson A.J., Uhr J.:Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria, Science 2004; 303, 1662–5
  12. Marlicz W, Starzyńska T, Marlicz K. :Pacjent z zespołem jelita nadwrażliwego w praktyce lekarza gastroenterologa Gastroenterologia Polska 2013; 20: 61–68
  13. Wasilewska E., Złotkowska D., Pijagin M. E.: Rola mikroflory jelitowej i bak- terii probiotycznych w profilaktyce i rozwoju raka jelita grubego. Postepy Hig Med Dosw. 2013; 67: 837–847
  14. Dudzińska E.: Wpływ mikroflory jelitowej na rozwój zespołu jelita drażli- wego. Medycyna Środowiskowa – Environmental Medicine 2016, Vol. 19, No. 3, 70–76
  15. Fasano A.: Leaky gut and autoimmune diseases. Clinic Rev Allerg Immunol 2012; 42: 71–78
  16. Gajewska J.: Błaszczyk M. K. Probiotyczne bakterie fermentacji mlekowej „LAB”. Podstawy Mikrobiologii.2012, 51, (1), 55–65
  17. Szajewska H.: Probiotyki w gastroenterologii – aktualny stan wiedzy (2015). Gastroenterologia Kliniczna 2015, tom 7, nr 1, 20–26
  18. Szajewska H.: Praktyczne zastosowanie probiotyków. Gastroenterologia Kli- niczna 2014; 6: 16-23
  19. Nowak A., Śliżewska K., Libudzisz Z., Socha J.: Probiotyki – efekty zdrowot- ne. Żywność. Nauka. Technologia. Jakość 2010; 4 (71), 20–36
  20. Aguirre, M. & Collins, M.D.: Lactic acid bacteria and human clinical infec- tions. J. Appl. Bact.1993. 75: 95–107. 4
  21. Gasser, F.: Safety of lactic acid bacteria and their occurrence in human clini- cal infections. Bull. Inst. Pasteur. 1994. 92: 45–67
  22. Salminen S., von Wright, A., Morelli, L., Marteau, P., et al.: Demonstration of safety of probiotics – a review. Int. J. Food Prot. 1998. 44: 93–106
  23. Yerzinkyan LA.: Biological characteristics of some species of lactic acid bac- teria. Yerevan: Academy of Science of Armenia; 1971.(RU)
  24. Yerzinkyan, L.A.: Biological Properties of Some Isolates of Lactic Acid Bac- teria. Yerevan: Academy of Sciences of Armenia. 1971. (RU)
  25. Yerzinkian L.: Preparation and use of therapeutic acidophilic milk and Na- rine milk. Publishing house of the academy of science of the Armenian SSR. Yerevan.p 13 1965. (RU)
  26. Yerzinkian L.:Biological peculiarities of some races of lactic-acid bacteria. Publishing house of the academy of science of the Armenian SSR. Yerevan.p 233.1971 (RU)
  27. Akopyan, G., Madoyan, K., Dilayan, E., Kanetani : Therapeutic Efects of Lac- tobacillus acidophillus Er-2 Strain 317/402, “NARINE’’. Milk Science Vol. 53, No. 2 2004
  28. Haykuhi C., Jung-Eun B., Heejun K., Myunghee K.: Rheological Properties and Volatile Composition of Fermented Milk Prepared by Exopolysacchari- de-producing Lactobacillus acidophilus n.v. Er2 317/402 Strain Narine. Bio- technology and Bioprocess Engineering 22: 327–338 (2017)
  29. Coconnier, M. H., Levin, V., Bernet-Camard, M. F., Hudault, S., and Servin, A. L.: Antibacterial effect of the adhering human Lactobacillus acidophilus strain LB. Antimicrob. Agents Chemother. 41, 1977, 1046–1052.
  30. Akeryan K. Bazukyan I.,Trochounian A.: Lactobacillus wyizolowane z mat- sunu, ormiańskiego fermentowanego produktu mlecznego: Właściwości wzrostu, aktywność przeciwbakteryjna i proteolityczna oraz ich zależność od pH. International Journal of Dairy Technology. 2016. tom 69
  31. G. Keryan, Y. A. Simonyan, I. L. Bazukyan, A. H. Trchounian.: Zahamo- wanie wzrostu i aktywność przeciwdrobnoustrojowa nowych szczepów Lactobacillus wyizolowanych z ormiańskiego produktu mlecznego matsun z EDTA w niskich stężeniach: Badanie porównawcze z bakteriami Gram- -dodatnimi i Gram-ujemnymi. Narodowa Akademia nauk w Armeni. nr 2. tom 114.2014
  32. Hakobyan, L.G. & Ghazaryan, Petros & Aleksandryan, M.A. & Harutyunyan, K.V. & Trchounian, Armen.: The probiotic strain of Lactobacillus acidophilus Er 317/402 “Narine” with high adhesive and antibiotic properties and its usage in acute childhood leuosis. Technologies of Living Systems. 2016. 13. 30–37
  33. Harutyunyan KV.:Adhesion of Probiotic Lactic Acid Bacteria as a Regula- tory Factor in the Normal Gastrointestinal Microbiota. Yerevan, Armenia: Scientific and Production Center “Armbiotechnology” NAS RA (2016)
  34. Mkrtchyan, H., Gibbons, S., Heidelberger, S., Zloh, M., and Limaki, K. H.: Purification, characterisation and identification of acidocin LCHV, an an- timicrobial peptide produced by Lactobacillus acidophilus n.v. Er 317/402 strain Narine. Int. J. Antimicrob. Agents 2010. 35, 255–260
  35. HaykuhiCharchoghlyan,HeejunKwon,Dong-JuHwang,JongSukLee1,Junsoo Lee, Myunghee Kim; Inhibition of Cronobacter sakazakii by Lactobacillus acido- philus n.v. Er2 317/402. Korean J. Food Sci. An. Vol. 36, No. 5, pp. 635–640. 2016
  36. Nazarov L.U., Sarkisyan V.G. Yerzinkyan L.A. Madoyan R. A.: Influence of “Narine” on the intestinal microflora. // Biological Journal of Armenia, v. 41, No. 12, 1988
  37. Avakyan A.O., Barsegyan A.A., Paronikyan R.V. : The course of the wound process under the influence of metabolic products of acido-lactic bacteria strain 317/402 “Narine”. // Epidemiology and prevention of hospital strains. Collection of scientific works, Yerevan, “Haiastan”, 1987
  38. A. O. Martirosyan Sh. L. Mndzhoyan, L. M. Charyan, L. G. Akopyan, and M. N. Nikishchenko: Antimicrobial Activity of Lactic Acid Bacteria from Sour Milk Products Narine, Karine, and Matsun. Applied Biochemistry and Mi- crobiology, Vol. 40, No. 2, 2004, pp. 178–180. Translated from Prikladnaya Biokhimiya i Mikrobiologiya, Vol. 40, No. 2, 2004, pp. 210–213
  39. Pepoyan, Astghik, Balayan, et all.: Probiotic Lactobacillus acidophilus Strain INMIA 9602 Er 317/402 Administration Reduces the Numbers of Candida albicans and Abundance of Enterobacteria in the Gut Microbiota of Familial Mediterranean Fever Patients. Frontiers in Immunology. 2018. 9. 10.3389
  40. Balayan, M., Manvelyan, A., Marutyan, Set all.: Impact of Lactobacillus aci- dophilus INMIA 9602 Er-2and Escherichia coli M-17 on some clinical blood characteristics of familial Mediterranean fever disease patients from the Ar- menian cohort. Int J Probiotics Prebiotics. 2015. 10, 91–95
  41. Pepoian, A., Arutunian, N., Grigorian, A., et all.: The certain clinical charac- teristics of blood inpatients with family Mediterranean fever of Armenian- population. Klin La Diagn.2015. 60,46–47
  42. Haruo Sugiuraa, Hiroko Sugiurab, Etsuo Ueyab, et all.: Enhanced macro- phage functions and cytokine production of lymphocytes after ingestion of bon narine in female BALB/c mice. Life Sciences 68. (2000).505–515
  43. Sukiasyan A.: Study of induction and regulation of synthesis of IL-1Beta and 1L-10 by human peripheral blood cultivated cells under the influence of Lactobacillus acidophilus „Narine” and other biologically active substances. PhD Thesis, Yerevan, Armenia. 2011.p105 (RU)
  44. Beisembaev E.A., Raisov T.K., Bugembaeva M.D.: Immunorehabilitation of patients with acute and chronic infections. v. 2, p. 54–63, Almati “Gilim”, Kazakhstan, 1997. Semipalatinsk State Medical Academy, Pavlodar Center of clinical immunology and reproduction
  45. Kita M.: Output of human interferon in cancer patients and healthy donors. Bulletin of Pastor Institute in Kioto, 1,1–13, 1987, (Japan)
  46. Kita M.: Produce of alpha and gamma interferon in patients with liver disea- ses, diabetes and chronic kidney pathology. // Bulletin of Pastor Institute in Kioto, 15–21, 1987, (Japan)
  47. Kita M., Kishida T.: Stimulation of interferon produce by “Narine” bacteria.
  48. Kita M., Kishida T.: Stimulation of interferon produce by Kikurage polysac- charide. // Clinical Report 1987, 21 (12), 71–74
  49. Harutyunyan V.M., Hakobyan G.S., Grigoryan E.G.: Experience of the “NA- RINE” drug administration (in capsules) in prophylaxis of the intestine dys- bacteriosis in antibiotic therapy. Yerevan State Medical University
  50. Hakobyan, L.G. Ghazaryan, Petros Aleksandryan, M.A. Harutyunyan, et all.: The probiotic strain of Lactobacillus acidophilus Er 317/402 “Narine” with high adhesive and antibiotic properties and its usage in acute child- hood leuconosis. Technologies of Living Systems. 13. 2016. 30–37
  51. Arutyunyan V.M., Hakopyan G.S., Grigoryan E.G.: Experience of “Narine” administration for prevention of the intestinal dysbacteriosis in antibiotic therapy. Yerevan State Medical Institute after M. Heratsi
  52. Afrikyan, E. and Khachaturyan, A.: Katalog kultur mikroorganizmov Cata- logue of Microorganism Cultures, Yerevan: Gitutyun, 1996, p. 211
  53. Erzinkyan, L.A., Shtamm bakterii Lactobacillus acidophilus, N.v. Er. 317/402, USSR Inventor’s Certificate no. 163573, Byull. Izobret., 1964, no. 13
  54. Nazarov L.U., Sarkisyan V.G.: Scientific-Research Institute of Proctology, Ministry of Health, Armenia
  55. Grigoryan E.G., Khachatryan O.Ts., Madoyan R.A.: Theoretical and applied aspects of gastroenterology. Scientific-Research Institute of Spa Treatment and Physical Medicine. Materials of the V Session of the Academy of Medi- cine, Yerevan, 2000
  56. Barsegyan R.G., Adamyan L.A., Demirchyan A.P.: Act on carrying out clini- cal trials of the procedure of lyophilizated drug administration in treatment and prophylaxis of intestinal dysbacteriosis in newborns and children of early age. Basis of the Department of Pediatrics No. 2 of the Yerevan Medical Institute, Children’s Clinical Hospital No. 3, 1991
  57. Mamaev D.B., Avakyan A.O., Yerzinkyan L.A.: The Department of Infectious Diseases with Children’s Infections of the Yerevan State Institute of Physici- ans’ Improvement, Laboratory of Nutrition Hygiene under the Armenian Re- search Institute of General Hygiene and Professional Diseases, Yerevan, 1979
  58. G.N. Matveev, M.E. Semendyaeva, M.G. Zhuravleva.“Medbioextrem” Fede- ral Administration under the Ministry of Health. Clinical testing of the “Na- rine” drug. Clinical Hospital No.83, 28 Orekhoviy Avenue, 115692 Moscow December 11, 1998
  59. M.A. Kvirkvelia, P.L. Sherbakov.The report on the result of clinical testing of the therapeutic product “Narine” of the “Vitamax-E” firm. Izmailovskaya Children’s city clinical hospital [RU]
  60. Dekhtsunian, K.M. and Ambartsumian, A.D.: Treatmentof the GI disbacte- riosis by introduction of the live lacticacid bacteria into the distal region of rectum. Russ J Microbiol Epidemiol Infect Dis. 1990, 2, 115–116 [RU]
  61. Panchishina M.V., Oleinik S.F.: Dysbacteriosis of the intestine, 1988
  62. Kim S.D., Korneva T.K., Khanina G.I.: Problems of proctology. M., 1984, issue 5, p. 71–74
  63. Suzdal’tsev A.A.: Collection of scientific works of the military-medical de- partment, Kuibyshev Medical Institute. 1979, No. 8, p. 73–74
  64. Сборник научных трудов «Наринэ» Витамакс-Е 2003г
  65. AkopyanG,MadoyanK.,DilanyanE.,KanetaniK.:TherapeuticEffectofLacto- bacillus Er-2 Strain 317/402 ”Narine” Milk Science, 2004 (Vol. 53 (N2)37–62
  66. Г. А Еганян, Э.К Диланян „Применение Наринэ в капсулах для профи- лактики и лечения ряда заболеваний” Вестник медицинского институ- та им. Меграбяна Ереван 2003г
  67. Grupa Robocza Polskiego Towarzystwa Gastroenterologi.: Postępowanie w zakażeniu Helicobacter pylori (rok 2000). Wytyczne. Gastoenterologia Pol. 2001, 8, 5–16
  68. Urban J.: Helicobacter pylori – charakterystyka i patogenność. Dent. Med. Probl. 2010, 47, 4, 482–486
  69. DyrlaP.,GilJ.,WojtuńS.,KorszunK.,KasińskaE.,MackiewiczA.:ZakażenieHe- licobacter pylori. Diagnostyka i leczenie. Pediatr Med Rodz 2015, 11 (1), p. 68–74
  70. Akopyan, G., R. Madoyan, E. Dilanyan, and K. Kanetani: Therapeutic effects of L. acidofilus n.v. Er-2 strain 317/402 “Narine”. Milk Sci. 2004.53: 35–63.
  71. Anisimova, T. I., R. A. Arakelyan: Bacterial strain L. acidophilus n.v Er-2 strain 317/402 Narine AAA used in the production of preparations and of dietetic, therapeutic and prophylactic products for treating dysbacteriosis and the consequences thereof. Euorpean Patent 1 186 654 A1.2002
  72. К.Г. Инджигулян: Влияние дополнительного назначения пробиотика «Нарине» на степень эрадикации, частоту реинфекции и рецидивов при терапии язвенной болезни, ассоциированной с хеликобактерио- зом. Национальный институт здравоохранения им. акад. С.Х. Авдал- бекяна МЗ РА 0051, Ереван, пр. Комитаса, 49/4
  73. Drzycimska-Tatka B., Drab-Rybczyńska A., Kasprzak J.: Zespół metabolicz- ny – epidemia XXI wieku. Hygeia Public Health 2011, 46(4): 423–430
  74. Volosnikova I.V., Shenderov B.A. Microecological approaches towards regu- lation of cholesterol metabolism. // Collected theses, II International sym- posium “Nutrition and health: biologically active food supplements”, M., April 25–27, 1996, P. 26–27
  75. Lentser A.A., Troshin A.A. To the question of cholesterolytic activity of lac- tobacilli. Success of medicine: Theses of reports – Tartu, 1986, P. 125–126
  76. Panchishina M.V. Clinico-experimental materials on the intestinal microf- lora participation in cholesterol metabolism in some internal diseases. Syn- opsis of Ph.D. thesis, M., 1988, P. 35
  77. Shenderov B.A., Manvelova M.A. Medical microbial ecology and functio- nal nutrition. Collected theses, II International symposium “Nutrition and health: biologically active food supplements”, M., 1996. P. 186–187
  78. R.A. Yeganyan. Study of influence of the “Narine” fermented milk product (capsulated form) on the cholesterol level of the blood serum in hypercho- lesterolemia. Research Center of Preventive Medicine, Ministry of Health, Russian Federation, Moscow
  79. Hirai Y., Hague V. Unique cholesterin glucosides in Helicobacter pylori. J. Bacteriol., 1995, 177, 18, 5327–5337
  80. V.M. Harutyunyan, E.G. Grigoryan, G.S. Hakobyan, E.S. Arumanyan. Chan- ges of the intestine microflora in chronic pancreatitis. Theses of reports of the V scientific-practical conference. September 21–22, 2000
  81. Nehring P, Mrozikiewicz-Rakowska B, Krasnodębski P, Karnafel W. Zespoł jelita drażliwego – nowe spojrzenie na etiopatogenezę. Prz Gastroenterol. 2011; 6 (1): 17–22
  82. Ю.В.Лобзин: Исследование клинической эффективности биологически активной добавки «Наринэ» у больных с синдромом раздраженного ки- шечника постинфекционного генеза. Министерство обороны Россий- ской Федерации Главное военное-медицинское управление Военно-меди- цинская академия Заместитель начальника академии по научной работе
  83. Т.Н.Матвеев: Клинические испытания препарата «Наринэ» для кор- рекции дизбактериоза кишечника для больных с органическими и функуиональными заболеваниями органов желудочно-кишечного тракта. Федеральное управление «Медбиоэкстрем» при МЗ РФ Кли- ническая больница No83 Главный врач Заслуженный врач РФ
  84. Nersessian A.K.. The possible clastogenic and anticlastogenic action of fer- mented milk “Narine” Abstracts. “Food and Cancer Prevention”. Internatio- nal Conference. Norwich. UK, 1992, page.104
  85. Nersessian A.K.. Possible clastogenic and anticlastogenic action of fermen- ted milk “Narine” Abstracts. “Food and Cancer Prevention/ Chemical and Biological Aspects” (K.W. Waldron, Ed.), Royal Society of Chemistry. Cam- bridge, 1993, page 62–64]; 55.
  86. НерсесянА.К.,ЗильфянВ.Н.,КумкумаджянВ.А.,Действиелактобацилл на мутагенную и противоопухолевую активность химиопрепаратов\\ Тезисы Юбилейной научной сессии ОНЦ им. В.А. Фанарджяна, Ереван, 1996, стр. 139–141
  87. Nersessian A.K. Antigentoxic action of «Narine» Lactobacilli in rat colon cells in vitro. Experi-mental Oncology. 2001. No 23. Р. 297-298
  88. Pepoyan, Astghik, Balayan, Marine, Malkhasyan et all.: Effects of Probiotic Lactobacillus acidophilus Strain INMIA 9602 Er 317/402 and Putative Pro- biotic Lactobacilli on DNA Damages in the Small Intestine of Wistar Rats In Vivo. Probiotics and Antimicrobial Proteins. 2018
  89. Matyukhin V.A. Academician of the Academy of Medicine of the USSR, Scientific-Research Institute of Radiation Medicine, Ministry of Health, Byelorussia, 1991
  90. Nersessian A.K. Possible clastogenic and anticlastogenic actions of fermen- ted milk «Narine» // In: Food and Cancer Prevention: Chemical and Bio- logical Aspects. The Proceedings of an International Conference (13-16 Sep. 1992, Norwich, UK). 1993. Р. 63-64
  91. A. K. Nersesyan. ANTIGENOTOXIC ACTION OF NARINE LACTOBA- CILLI IN RAT COLON CELLS IN VITRO. Experimental Oncology 23, 297–298, 2001 (December)
  92. Nersesyan AK. Possible clastogenic and anticlastogenic action of fermented milk Narine. In: Food and Cancer Prevention. Waldron KW, ed. Cambridge, UK : Royal Soc of Chem Publ 1993; 624.
  93. Pool-Zobel BL, Bertram B, Knoll M, Lambertz R, Neudecker C, Schillinger U, Schmezer P, Holzapfel WH. Antigenotoxic properties of lactic acid bacte- ria in vivo in the gastrointestinal tract of rats. Nutr Cancer 1993; 20: 27181.
  94. Nersessian A.K. Possible clastogenic and anticlastogenic actions of fermen- ted milk «Narine» // In: Food and Cancer Prevention: Chemical and Biolo- gical Aspects. The Proceedings of an Interna-tional Conference (13-16 Sep. 1992, Norwich, UK). 1993. Р. 63-64
  95. Oganesyan N.M., Malikoyan S.A., Yerzinkyan L.A., Madoyan R.A., Melikyan I.E. – Correction of the intestinal microflora in persons subjected to small doses of ionizing radiation by means of lyophilizated drug “Narine”. – Scientific-Rese- arch Institute of Medical Radiology, Ministry of Health, Armenia, Yerevan, 1991
  96. Dekhtsunyan K.M., Antonova S.A., Hambartsumyan K.F. – Prophylaxis and treatment of mammary gland nipple cracks in puerpera by the culture of acido-lactic bacteria strain 317/402. Yerevan, 1985
  97. Arakeljan, R.:Vaginal microbiocenosis dynamics in the course of the treat- ment of ginecological patients with the purified metabolic products of the lactic acid bacteria fermentation. Armenian Med Sci 41, 2001. 108–112
  98. Shungin I.O., Radzinskiy V.E., Tkacheva I.N. Biologically active supple- ments in treatment of inflammatory diseases of female genital sphere. – Collected theses, II International symposium “Nutrition and health: biolo- gically active food supplements”, M., 1996. P.190–191
  99. HambartsumyanA.D.,AntonovaS.A.,YerzinkyanL.A.–Useofacido-lacticbac- teria “Narine” for prophylaxis of staphylococci aureus carrier. All-Union scienti- fic-practical conference “Problems of clinical microbiology in non-infectious cli- nics”. Abstracts of reports, May 18–19, 1983, Vinnina town, Moscow, 1983, p. 268.
  100. Шунгин И. О., Радзинский В. Е., Ткачева И.Х. БАД в лечении воспа- лительных заболеваниий женской половой сферы.- СБ. Тезисов 2 Международного симпозиума «Питание и здоровъя»: биологически активные добавки, М., 1996, 190–191.
  101. Г.А. Еганян, Э. К. Диланян: ПРИМЕНЕНИЕ «НАРИНЭ» ДЛЯ ПРО- ФИЛАКТИКИ И ЛЕЧЕНИЯ РЯДА ЗАБОЛЕВАНИЙ
  102. Niphontova L.V. – Chief Children’s Endocrinologist, Kiev, Popova V.V. : Act on carrying out clinical trials of the dry lyophilizated drug “Narine” in treatment of children with severe forms of insulin-dependent diabetes mellitus. Clinical basis of the Department of Endocrinology of Children’s Clinical Hospital No. 14, 1992
  103. Apoyan N.A., Tumadjyan A.E., Melkonyan Zh.S., Avakyan A.V., et al.: An- tiinflammatory properies of metabolic products of acido-lactic bacteria strain 317/402 Narine. Journal of Experimental and Clinical Medicine of the Academy of Sciences, Armenia, 1985, v. XXV, No. 6, p. 600

Veröffentlichte Informationen dienen nur zu Informationszwecken und können die Konsultation eines Arztes oder Apothekers nicht ersetzen. Unter keinen Umständen dür- fen sie verwendet werden, um im Falle einer Krankheit oder eines Gesundheitsproblems eine medizinische Diagnose zu stellen, oder, um die in der Veröffentlichung vorgestellten Präparate aufzuzeichnen oder zu verwenden. Fragen Sie in jedem Fall Ihren Arzt oder Apotheker. Jede Nutzung oder Verwendung der im Material enthaltenen Präparate darf nur nach vorheriger Absprache mit einem Arzt oder Apotheker und nach Lesen der je- dem verkauften Produkt beigefügten Informationen erfolgen.

Das Material kann Meinungen von Experten in Bereichen enthalten, die sich auf den Inhalt der Website des Herausgebers beziehen, oder Auszüge aus Presseartikeln. Alle diese Informationen sind ausschließlich die Meinungen von Experten, die sie geäußert haben, oder Veröffentlichungen Dritter sind, und stellen daher nicht unbedingt die An- sichten des Herausgebers dar. Expertenmeinungen spiegeln ihre persönlichen Ansichten wider und sollten niemals als Meinungen oder Verpflichtungen des Herausgebers inter- pretiert werden.